Infliximab showed no clear difference in serious adverse events (at 52 weeks) compared with biosimilar (low certainty).
It is very uncertain whether infliximab changes serious adverse events (at 56 weeks) compared with adalimumab (very low certainty).
It is very uncertain whether infliximab changes serious adverse events (at 54 weeks) compared with placebo (very low certainty).
Infliximab may leads to higher withdrawal due to adverse events (at 52 weeks) compared with biosimilar (low certainty).
It is very uncertain whether infliximab changes withdrawal due to adverse events (at 56 weeks) compared with adalimumab (very low certainty).
It is very uncertain whether infliximab changes withdrawal due to adverse events (at 32‐54 weeks) compared with placebo (very low certainty).
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in adverse events up to week 10 compared with placebo and two infusions of infliximab (moderate certainty).
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in serious adverse events up to week 10 compared with placebo and two infusions of infliximab (low certainty).
Infliximab 5 mg/kg and purine analogues showed no clear difference in withdrawals due to adverse events at week 26 compared with purine analogues alone (low certainty).
It is very uncertain whether infliximab combined with purine analogues changes withdrawal due to adverse events (at 48 weeks) compared with purine analogues (very low certainty).
It is very uncertain whether infliximab combined with purine analogues changes serious adverse events (at 48 weeks to 2 years) compared with purine analogues (very low certainty).
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in withdrawal due to adverse events up to week 10 compared with placebo and two infusions of infliximab (low certainty).